However, because DNA methylation is reversible, it represents a compelling therapeutic target – a concept that has been validated by the clinical activity of hypomethylating agents in myeloid malignancies as well as the mutation-specific inhibition of neomorphic enzyme function in IDH1- and IDH2-mutated AML [34–37]. This evidence concerns the gene IDH1 and acute myeloid leukemia.